|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Toxicology/Mousegenetics, Johannes Gutenberg-Universitat Mainz, Germany
2 Division of Molecular Genetics and Center of Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, Netherlands
3 FACS and Array Core Facility, Johannes Gutenberg-Universitat Mainz, Mainz, Germany
4 Academic Medical Center, AMC Liver Center, The Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Genetics and Center of Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, Netherlands
5 Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, Netherlands
* To whom correspondence should be addressed. E-mail: bockamp{at}mail.uni-mainz.de.
Ligand-activated Cre recombinases are widely used for studying gene function in vitro and in conditional mouse models. To compare ligand-dependent Cre recombinases, different Cre estrogen receptor fusions were introduced into the ROSA26 locus of embryonic stem (ES) cells and assayed for genotoxicity and recombination efficiency. Of the tested recombinases, the CreERT2 variant showed no toxicity and was highly responsive to ligand induction. To constitutively express CreERT2 in mice and to also clarify if the CreERT2 system displays background activity, we generated a knock-in mouse line harbouring the CreERT2 coding region under the control of the ROSA26 locus. Analysis of this ROSA26 CreERT2 deleter mouse with different reporter strains revealed ubiquitous recombination in the embryo, partial recombination in peripheral and haematopoietic tissues but no effective CreERT2 expression in the brain. Furthermore, using flow cytometry we found low level background recombination in non-induced bi-transgenic ROSA26 CreERT2/EGFP reporter mice. To determine whether background activity poses a general problem for conducting conditional in vivo experiments with the ROSA26 CreERT2 deleter, we used a sensitive conditional skin cancer model. In this assay cancer induction was completely restricted to induced bi-transgenic CreERT2/K-RasV12 mice whereas non-induced control animals did not show any sign of cancer indicating the usefulness of the ROSA CreERT2 system for regulating conditional gene expression in vivo. The ROSA26 CreERT2 deleter strain will be a convenient experimental tool for studying gene function under circumstances requiring partial induction of recombination in peripheral tissues and will be useful for uncovering previously unknown or unsuspected phenotypes.
This article has been cited by other articles:
![]() |
A. Uhmann, K. Dittmann, J. Wienands, and H. Hahn Comment on "Direct Hematological Toxicity and Illegitimate Chromosomal Recombination Caused by the Systemic Activation of CreERT2" J. Immunol., September 1, 2009; 183(5): 2891 - 2891. [Full Text] [PDF] |
||||
![]() |
C. G. Crist, D. Montarras, G. Pallafacchina, D. Rocancourt, A. Cumano, S. J. Conway, and M. Buckingham Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression PNAS, August 11, 2009; 106(32): 13383 - 13387. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zibat, A. Uhmann, F. Nitzki, M. Wijgerde, A. Frommhold, T. Heller, V. Armstrong, L. Wojnowski, L. Quintanilla-Martinez, J. Reifenberger, et al. Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts Carcinogenesis, June 1, 2009; 30(6): 918 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Horman, C. S. Velu, A. Chaubey, T. Bourdeau, J. Zhu, W. E. Paul, B. Gebelein, and H. L. Grimes Gfi1 integrates progenitor versus granulocytic transcriptional programming Blood, May 28, 2009; 113(22): 5466 - 5475. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Velu, A. M. Baktula, and H. L. Grimes Gfi1 regulates miR-21 and miR-196b to control myelopoiesis Blood, May 7, 2009; 113(19): 4720 - 4728. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |